UK AND EUROPEAN BIOTECHS. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : UK AND EUROPEAN BIOTECHS.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: UPAL who wrote (49)	3/9/1997 3:48:00 PM
From: James Reynolds	of 64

UPAL, I don't hold BTG - someone pointed out its merits to me at around the œ4 level before the share split. I wanted to find out more before buying but the shares went racing away, and within a few weeks were around the œ10-11 before eventually heading over œ20. With hindsight I should have bought even at around the œ10 level but as you say so many good opportunities around so little money. I subscribe to Techinvest which is excellent, although it does not cover as many biotechs as I would like. You are right about the FT bio, I saw a sample issue which was good but the subscription cost was very high. A stock which I think holds great potential is Ethical Holdings (ETHCY). Ethical is UK-headquartered but listed on Nasdaq. The company has a market value of around $70 million, but has investments worth over $27 million including a 28.5% stake in UK-based biotech Phytopharm and an 18% stake in Nasdaq-listed Mediject. Apart from this it holds major collaboration deals with Elan, Schein and Searle for its drug delivery products. Have a look at the Ethical thread I started for a breakdown of its valuation (note Phytopharm has fallen back a bit since I posted the article so the Ethical stake is worth a little less now). Ethical's valuation seems ludicrous and I have heard they are looking to a secondary London listing sometime this year which should lead to a re-rating. If you want to get an investor pack then you can e-mail the company's Head of Corporate Affairs, Justin Gover, on <justin.gover@ethical.co.uk> I think you will surprised by the lowly valuation of this company compared with its potential. Do you hold shares in any US biotechs?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next